Portfoliotracker

Ardelyx, Inc.

ARDX · NASDAQGM · Healthcare Biotechnology 23/100 E

3,070 $
▼ −0,020 (−0,65 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 12:43
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score23 / 100 Market cap768 mil. $ P/E– Forward P/E19,5 P/S1,6 P/B4,7 EV/EBITDA– Dividend yield– FCF yield-2,08 % EPS-0,23 $ Net margin-11,8 % Return on equity-34,9 % Beta0,77 Debt / equity1,73
52-week range 2,80 to 8,40
3-month average volume4,4 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Employees
489
Country
United States
Fiscal year end
31. 12.
Data since
19. 6. 2014

Explore further

Similar companies AKBACTMXTGTX

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account